



Description générale

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

INN	Bevacizumab
Codes ATC	S01LA08
Type de médicament	Biological agent
Historique des statuts LME	Ajouté pour la première fois en 2013 (TRS 985) pour Age related macular degeneration
Wikipédia	Bevacizumab ↗
DrugBank	Bevacizumab ↗

Recommandations

Section Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age related macular degeneration

